Aardvark Therapeutics, Inc. (NASDAQ:AARD) CFO Purchases $160,000.00 in Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CFO Nelson Sun purchased 10,000 shares of the business’s stock in a transaction on Friday, February 14th. The stock was acquired at an average price of $16.00 per share, with a total value of $160,000.00. Following the completion of the acquisition, the chief financial officer now directly owns 99,484 shares in the company, valued at $1,591,744. The trade was a 11.18 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Aardvark Therapeutics Stock Up 9.9 %

NASDAQ:AARD opened at $14.90 on Thursday. Aardvark Therapeutics, Inc. has a fifty-two week low of $11.55 and a fifty-two week high of $16.48.

Aardvark Therapeutics Company Profile

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.